# EDGAR Filing Document

**Accession Number:** 0001607962
**File Stem:** 0001178913-25-002629
**Filing Date:** 2025-8
**Character Count:** 10907
**Document Hash:** d64549bac862b3c98fdab8bb61813b4e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-25-002629.hdr.sgml**: 20250805

**ACCESSION NUMBER**: 0001178913-25-002629

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250801

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250805

**DATE AS OF CHANGE**: 20250805

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lifeward Ltd.
- **CENTRAL INDEX KEY:** 0001607962
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36612
- **FILM NUMBER:** 251182947

**BUSINESS ADDRESS:**
- **STREET 1:** 200 DONALD LYNCH BLVD.
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752
- **BUSINESS PHONE:** 15082511154

**MAIL ADDRESS:**
- **STREET 1:** 200 DONALD LYNCH BLVD.
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ReWalk Robotics Ltd.
- **DATE OF NAME CHANGE:** 20140620

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Argo Medical Technologies Ltd.
- **DATE OF NAME CHANGE:** 20140513

?xml version='1.0' encoding='ASCII'?

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 1, 2025

Lifeward Ltd.

------

(Exact Name of Registrant as Specified in its Charter)

<u> Israel </u> <u> 001-36612 </u> <u> Not Applicable </u> <br> (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

<u> 200 Donald Lynch Blvd. Marlborough, MA </u> <u> 01752 </u> <br> (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: +508.251.1154

Not applicable<br>

(Former name or former address, if changed since last report)

**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))**

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** <br>| **Name of each exchange on which registered** |
| Ordinary Shares, par value NIS 1.75<br>| LFWD<br>| Nasdaq Capital Market<br>|

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On August 1, 2025, Lifeward Ltd. (the "Company") held its 2025 Annual Meeting of Shareholders (the "Meeting"), at which the Company's shareholders approved the Company's 2025 Incentive Compensation Plan (the "Plan"), which provides for the grant of stock-based awards to officers, directors and employees of the Company. A description of the material terms of the Plan is contained in the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission ("SEC") on June 26, 2025 (the "Proxy Statement"). The description of the Plan is qualified in its entirety by reference to the plan document attached hereto as Exhibit 10.1, which is incorporated by reference into this Item 5.02.

 **Item 5.07 Submission of Matters to a Vote of Security Holders.**

An aggregate of 5,223,471 ordinary shares, or approximately 45.0% of the Company's 11,602,266 ordinary shares issued and outstanding as of June 23, 2025, the record date for the Meeting, were present or voted at the Meeting, constituting a quorum. The following proposals were voted upon at the Meeting, with the results of such voting as set forth below. Proposals No. 1.a, 1.b, 1.c, 2, 3, 4, 6, 7 and 8 received the requisite level of approval by shareholders. Proposal 5 did not receive the requisite level of support. The proposals are described in greater detail in the Proxy Statement.

#### Results of the Meeting
***Proposal No. 1.a:*** To reelect Mark Grant as a Class II director of the Board, to serve until the 2028 annual meeting of shareholders and until his successor has been duly elected and qualified, or until his office is vacated in accordance with the Company's Articles of Association or the Israel Companies Law, 5759-1999.

---

| | | | |
|:---|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstain</u>** | **<u>Broker Non-Votes</u>** |
| 1,585,715 | 219,013 | 10,296 | 3,408,447 |

---

***Proposal No. 1.b:*** To reelect Dr. John William Poduska as a Class II director of the Board, to serve until the 2028 annual meeting of shareholders and until his successor has been duly elected and qualified, or until his office is vacated in accordance with the Company's Articles of Association or the Israel Companies Law, 5759-1999.

---

| | | | |
|:---|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstain</u>** | **<u>Broker Non-Votes</u>** |
| 1,195,339 | 612,112 | 7,574 | 3,408,446 |

---

***Proposal No. 1.c:*** To reelect Randel E. Richner as a Class II director of the Board, to serve until the 2028 annual meeting of shareholders and until her successor has been duly elected and qualified, or until her office is vacated in accordance with the Company's Articles of Association or the Israel Companies Law, 5759-1999.

---

| | | | |
|:---|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstain</u>** | **<u>Broker Non-Votes</u>** |
| 1,189,131 | 618,927 | 6,967 | 3,408,446 |

---

***Proposal No. 2:*** To ratify the compensation payable to Mark Grant, the Company's new President and Chief Executive Officer.

---

| | | | |
|:---|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstain</u>** | **<u>Broker Non-Votes</u>** |
| 1,114,794 | 684,656 | 15,575 | 3,408,446 |

---

***Proposal No. 3:*** To approve the payment to the individual serving as the Company's Chairperson of the Board from time to time of an annual fee and an annual equity grant (or cash fee in lieu of an equity grant) that are double the amounts received by other directors of the Company from time to time, effective with the date of the Meeting.

---

| | | | |
|:---|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstain</u>** | **<u>Broker Non-Votes</u>** |
| 1,340,307 | 462,002 | 12,716 | 3,408,446 |

---

***Proposal No. 4:*** To approve the Lifeward Ltd. 2025 Incentive Compensation Plan.

---

| | | | |
|:---|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstain</u>** | **<u>Broker Non-Votes</u>** |
| 1,179,799 | 625,682 | 9,544 | 3,408,446 |

---

------

***Proposal No. 5:*** To ratify the shareholders' previous approval of the issuance of equity compensation (under, and subject to the approval of, Proposal 4) to Ms. Randel E. Richner, a member of the Board, in connection with the additional consulting services provided by Ms. Richner under the Consulting Agreement with Richner Consultants, LLC, a Delaware company owned by Ms. Richner.

---

| | | | |
|:---|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstain</u>** | **<u>Broker Non-Votes</u>** |
| 811,866 | 993,112 | 10,047 | 3,408,446 |

---

***Proposal No. 6:*** To approve amendments to the Company's Articles of Association authorizing an increase in the Company's authorized share capital.

---

| | | | |
|:---|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstain</u>** | **<u>Broker Non-Votes</u>** |
| 1,360,295 | 445,416 | 9,314 | 3,408,446 |

---

***Proposal No. 7:*** To approve the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company's independent registered public accounting firm for the year ending December 31, 2025 and until the next annual meeting of shareholders, and to authorize the Board, upon recommendation of the audit committee, to fix the remuneration of said independent registered public accounting firm.

---

| | | |
|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstain</u>** |
| 4,247,130 | 867,401 | 108,940 |

---

***Proposal No. 8:*** To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to Item 402 of Regulation S-K of the SEC, including the compensation tables and accompanying narrative disclosures.

---

| | | | |
|:---|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstain</u>** | **<u>Broker Non-Votes</u>** |
| 1,129,220 | 658,819 | 26,986 | 3,408,446 |

---

#### Item 9.01. Financial Statements and Exhibits.
**(d) Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [10.1](https://www.sec.gov/Archives/edgar/data/1607962/000117891325002243/zk2533377.htm#APPENDIXB) | [Lifeward Ltd. 2025 Incentive Compensation Plan.](https://www.sec.gov/Archives/edgar/data/1607962/000117891325002243/zk2533377.htm#APPENDIXB) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **Lifeward Ltd.** | **Lifeward Ltd.** |
| By:  | <u>/s/ William Mark Grant</u> |
| Name: <br> Title: | William Mark Grant<br> President and Chief Executive Officer |

---

Dated: August 5, 2025

------